Trial · NCT05049863
Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)
NCT05049863, Phase 1, Terminated, Washington University School of Medicine
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial). Trials, record NCT05049863. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05049863
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)
- NCT number
- NCT05049863
- Status
- Terminated
- Phases
- Phase 1
- Enrollment
- 17 participants, actual
- Lead sponsor
- Washington University School of Medicine
- Conditions
- Small-cell Lung Cancer, Small Cell Lung Carcinoma
- Interventions
- Mycophenolate Mofetil, Allopurinol, Irinotecan
- First posted
- 2021-09-20
- Last updated
- 2024-12-05
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of study treatment related adverse events as measured by NCI-CTCAE v 5.0 (Phase I only) | Through 30 days after completion of treatment (estimated to be 5 months) | |
| Primary | Overall response rate (ORR) (Phase II and phase I patients who receive the MTD) | Through completion of treatment (estimated to be 4 months) | * ORR is defined as the proportion of patients achieving a complete response (CR) or partial response (PR) according to RECIST 1.1 * Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Disappearance of all non-target lesions and normalization of tumor marker level. * Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. |
| Primary | Recommended phase II dose (RP2D) (Phase I only) | Completion of cycle 1 (each cycle is 21 days) of all enrolled Phase I participants (estimated to be 10 months) | -The recommended phase II dose (RP2D) is defined as the dose level at which fewer than 2 patients of a cohort of 6 patients experience dose-limiting toxicity during the first cycle. |
| Primary | Number of discontinuations due to treatment related adverse events (Phase I only) | Through completion of treatment (estimated to be 4 months) | |
| Primary | Number of DLTs in Phase I patients | Completion of cycle 1 (each cycle is 21 days) of all enrolled Phase I participants (estimated to be 10 months) | |
| Secondary | Progression-free survival (PFS) (Phase II and phase I patients who receive the MTD) | Through 6 months after completion of treatment (estimated to be 10 months) | -Progression-free survival (PFS), defined as the duration of time from the start date of study treatment to the date of earliest progression or death, whichever occurs first. Patients who neither progress nor die by the data cutoff date will be censored at the last follow up date. |
| Secondary | Overall survival (OS) (Phase II and phase I patients who receive the MTD) | Through 6 months after completion of treatment (estimated to be 10 months) | -Overall survival (OS), defined as the duration of time from the start date of study treatment to death from any cause. Patients who are alive by the data cutoff date will be censored at the last follow up date. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05049863
GET https://conductscience.org/api/trials/v1/NCT05049863/registered